Table 2:
The metabolite concentrations and T2B values of the patients and control subjects*
| Subjects | Metabolite Concentrations (mmol/kg brain) |
T2B Values (ms) | ||
|---|---|---|---|---|
| N-acetylaspartate | Creatine | Choline | ||
| First-episode group | ||||
| Patients (n = 12) | 8.97 ± 0.82 | 3.63 ± 0.23 | 1.21 ± 0.08 | 76.17 ± 12.26 |
| Controls (n = 14) | 10.41 ± 0.45 | 3.56 ± 0.27 | 1.18 ± 0.07 | 57.93 ± 6.85 |
| Significance | P < .001 | P = .54 | P = .39 | P < .001 |
| Chronic group | ||||
| Patients (n = 16) | 8.86 ± 0.89 | 3.68 ± 0.35 | 1.22 ± 0.09 | 78.03 ± 12.09 |
| Controls (n = 14) | 10.40 ± 0.44 | 3.72 ± 0.25 | 1.26 ± 0.10 | 60.57 ± 7.85 |
| Significance | P < .001 | P = .66 | P = .99 | P < .001 |
| Combined group | ||||
| Patients (n = 28) | 8.91 ± 0.84 | 3.65 ± 0.30 | 1.24 ± 0.11 | 77.23 ± 11.97 |
| Controls (n = 28) | 10.40 ± 0.44 | 3.64 ± 0.27 | 1.22 ± 0.10 | 59.25 ± 7.35 |
| Significance | P < .001 | P = .84 | P = .45 | P < .001 |
*
Data are given as mean ± SD.